These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34452170)

  • 1. The Therapeutic Effect of Human Serum Albumin Dimer-Doxorubicin Complex against Human Pancreatic Tumors.
    Kinoshita R; Ishima Y; Chuang VTG; Watanabe H; Shimizu T; Ando H; Okuhira K; Otagiri M; Ishida T; Maruyama T
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
    Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
    Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
    Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
    Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
    Zheng K; Li R; Zhou X; Hu P; Zhang Y; Huang Y; Chen Z; Huang M
    Int J Nanomedicine; 2015; 10():5327-42. PubMed ID: 26346331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy.
    Kang NW; Lee JY; Kim DD
    J Control Release; 2022 Feb; 342():111-121. PubMed ID: 34990700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine.
    Ishima Y; Fang J; Kragh-Hansen U; Yin H; Liao L; Katayama N; Watanabe H; Kai T; Suenaga A; Maeda H; Otagiri M; Maruyama T
    J Pharm Sci; 2014 Jul; 103(7):2184-2188. PubMed ID: 24846171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-triggered drug-release vehicles for synergistic cancer therapy.
    Tu TY; Yang SJ; Tsai MH; Wang CH; Lee SY; Young TH; Shieh MJ
    Colloids Surf B Biointerfaces; 2019 Jan; 173():788-797. PubMed ID: 30384276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System.
    Ishima Y; Maruyama T; Otagiri M; Ishida T
    Chem Pharm Bull (Tokyo); 2020; 68(7):583-588. PubMed ID: 32611995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity.
    Zhang B; Wan S; Peng X; Zhao M; Li S; Pu Y; He B
    J Mater Chem B; 2020 May; 8(17):3939-3948. PubMed ID: 32236239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
    Wu J; Tang C; Yin C
    Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD19 mAb-conjugated human serum albumin nanoparticles effectively deliver doxorubicin to B-lymphoblastic leukemia cells.
    Pan H; Li S; Li M; Tao Q; Jia J; Li W; Wang L; Guo Z; Ma K; Liu Y; Cui C
    Pharmazie; 2020 Jul; 75(7):318-323. PubMed ID: 32635973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model.
    Gou Y; Zhang Z; Li D; Zhao L; Cai M; Sun Z; Li Y; Zhang Y; Khan H; Sun H; Wang T; Liang H; Yang F
    Drug Deliv; 2018 Nov; 25(1):321-329. PubMed ID: 29350051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake.
    Chaiwaree S; Prapan A; Suwannasom N; Laporte T; Neumann T; Pruß A; Georgieva R; Bäumler H
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32131545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
    Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
    Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-sensitive Au-BSA-DOX-FA nanocomposites for combined CT imaging and targeted drug delivery.
    Huang H; Yang DP; Liu M; Wang X; Zhang Z; Zhou G; Liu W; Cao Y; Zhang WJ; Wang X
    Int J Nanomedicine; 2017; 12():2829-2843. PubMed ID: 28435261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview on the delivery of antitumor drug doxorubicin by carrier proteins.
    Agudelo D; Bérubé G; Tajmir-Riahi HA
    Int J Biol Macromol; 2016 Jul; 88():354-60. PubMed ID: 27037051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.